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vABSTRACT
Objective
The use of conformal radiation therapy in the treatment of carcinoma of the prostate has
allowed for dose escalation and improved local control. The dose to the rectum is an
important consideration in determining complication rates. This study aims to evaluate
the effect of a Foleys rectal catheter balloon on the dose volume histograms to the rectum
and to assess the effect of the balloon catheter on prostate gland immobilization during
treatment of intermediate risk cancer of the prostate.
Design and methods
Ten patients with intermediate risk prostate cancer, each acting as his own control, were
recruited in the study; eight patients had complete data for analysis. CT scans were done
at intervals during treatment, with and without a rectal balloon filled with 30 ml of
contrast. 3 pairs of CT scans for each patient were performed and were available for
analysis. All patients were treated with 6-field conformal radiotherapy up to 66 Gy
followed by a boost of 12 Gy in 3 fractions to the prostate using a rectal balloon and a 3-
field plan. Dose volume histograms were calculated for the boost plan with and without
the rectal balloon. Movements of the prostate in the superior-inferior and the anterior-
posterior directions were measured with and without the balloon for each treatment.
Results
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There was a slight reduction in the dose received by 1% and 2 % of the rectal volume
with the balloon (55% and 52% respectively), compared to without a balloon (57% and
54.3% respectively)   (p> 0.05). There was a non significant increase in the dose received
by 50% of the rectum (p>0.05) with the use of the rectal balloon due to the rectum being
pushed towards the symphysis pubis by the balloon.
With the use of rectal balloon, the superior / inferior displacement of the prostate was
reduced (p=0.04) and a displacement of more than 5 mm was observed in one out of eight
patients. The anterior / posterior displacement of the prostate was decreased with the
rectal balloon with a mean of 4 mm compared to 5 mm with no rectal balloon. This was
not statistically significantly (p>0.05). However, displacement of more than 5 mm was
observed in 2 patients with the rectal balloon. No grade 3 acute rectal toxicity was
recorded in the 8 patients.
Conclusion
There was no significant change in the percentage dose received by the rectum with the
use of the rectal balloon in this study. The study showed however that the rectal balloon
significantly reduced prostate movement during treatment.
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1INTRODUCTION
1.1    Background
Prostate cancer is second to lung cancer as a cause of male cancer mortality. The
incidence of the disease escalates with age with a median age at diagnosis of 68 years.
The lifetime risk for prostate cancer in American men is one in six (1). In South Africa, a
total of 2802 and 3715 new cases were reported in 1996 and 1997, respectively. These
comprised on average 12% of all male cancer cases per year. The lifetime risk of
developing cancer of the prostate in all men in South Africa was 1: 24 in 1997 (2). It is
therefore one of the common causes of morbidity and mortality in men in South Africa.
With the introduction of Prostate Specific Antigen (PSA) as a screening tool for this
disease in United States of America (USA), the number of patients diagnosed with
prostate cancer increased, especially in the organ confined disease.
The incidence of microscopic extension beyond the capsule of the prostate gland in
patients with organ confined disease ranges between 8 and 57% (1) and several
alogarisms, normogrms and risk group classification schemes that are currently relevant
to radiotherapy treatment of localised prostate cancer are in use (3). Nomograms that
predict the probability of pathological end points have been described in literature. Partin
et al. (4) developed such nomograms which are widely recognised and used to predict the
extent of disease in localised prostate cancer. The tables have been since revised by
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2Partin (5) as shown in appendix A.  Roach et al. (6) developed 3 relatively simple
formulae shown below to estimate the probability of lymph node (LN), extra capsular
extension (ECE) and seminal vesicle (SV) involvement based on Partin's original
nomograms.
1. ECE  = (3/2) x PSA + [(GS- 3) x 10]
2. +SV  = (3/3) x PSA + [(GS-6) x 10]
3. +LN  = (2/3) x PSA + [(GS-6) x 10]
These have been shown to predict biochemical failure in patients under going external
beam radiotherapy (7).
1.1.1 Prognosis
The most important predictors of the extent of disease in localised prostate cancer are the
pre-treatment PSA, primary tumour stage and pathological tumour differentiation. The
other important predictor of survival are the presence of perineural invasion and number
of positive biopsies (8 9 10). The TNM staging (appendix B) fails to include all of these
prognostic features and the current practice in treatment centres is to stratify the patients
into risk groups using known prognostic features.
In the commonly used stratification systems, which were first used by investigators from
Harvard and Memorial Sloan Kettering Cancer Center (MSKCC) (11, 12), patients are
stratified into low, intermediate and high risk groups (Table 1).
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3Table 1. Prostate Cancer Risk Groups
Low risk group  Intermediate risk group  High risk group
Gleason score 2-6 7 8-10
T stage  T1c-T2a T2b Or T2c/T3
Pre-treat. PSA <10 ng/l 10-20 ng/l >20 ng/l
KEY -  Pre-treat. PSA =Pre-treatment Prostate Specific Antigen
1.1.2 Treatment options
The optimal treatment of localised prostate cancer remains controversial. The natural
history of the tumour is influenced by multiple prognostic factors and various treatment
options that affect the quality of life of the patient.
Presently, for patients with low risk disease having similar prognostic features, there are
no differences in biochemical or disease free survival (DFS) outcome when treated with
radical prostatectomy (RP), high dose external beam radiotherapy (EBRT),
brachytherapy (1).
For patients in the intermediate risk group and selected high risk patients, high dose
EBRT has shown a gain in the 5-year no biochemical evidence of disease (bNED).
External Beam Radiation Therapy (EBRT) plus brachytherapy with a permanent implant
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4or High Dose Rate (HDR) brachytherapy as a boost can be used and for highly selected
cases, RP may be an option.
For patients with involvement of the capsule or a Gleason Score of 8 or higher, a
treatment option is high dose EBRT, with or without hormonal therapy. For patients with
T4, positive lymph nodes or metastatic disease, hormonal therapy for an indefinite period
is the standard. For hormonal refractory disease, chemotherapy with Taxols, Carboplatin
or Mitoxanthrone is an option (1).
1.2 Treatment technique
1.2.1 Radical prostatectomy
This involves the removal of the prostate, seminal vesicles, ampullae, vas deferens and
bilateral lymph node dissection. With modern surgical techniques, sexual function is
preserved in 73% of patients but this is correlated with age.
DocumentsPDFComplete
Click Here & Upgrade
Expanded Features
Unlimited Pages
51.2.2 Radiation therapy
1.2.2.1 Conventional EBRT
This is usually limited to 6 x 6 cm or 8 x 8 cm fields around the prostate commonly using
a 4-field box technique for T1/T2 disease with favourable features (1). However if the
seminal vesicles or the lymph nodes are involved, then the whole pelvis is treated up to
45 Gy and this is followed with a boost to 70 Gy to the prostate. These old techniques not
only used low dose but were also using small boost fields and routinely using bony land
marks for the treatment borders, these problems have been over come by the 3-DCRT
and more of recent the use of IMRT.
1.2.2.2 3-Dimensional Conformal Radiation Therapy (3DCRT)
This method allows delivery of higher doses of radiation to target volume while sparing
surrounding normal tissues and is based on CT scanning, which images the prostate and
other structures in the pelvis and generates high resolution 3-Dimensional reconstructions
of the patient’s anatomy. The volumetric data is used for treatment planning after the
physician has outlined the Gross Tumour Volume (GTV) and the critical structures.
Multi-Leaf Collimators (MLC) or blocks are used to shape the beams. The Dose Volume
Histograms (DVHs) generated are used to check the dose to the tumour and critical
structures. Using the critical volume tolerance method during the 3-DCRT, there is 30%
reduction in dose received by 50% of the rectum, making it possible to increase minimum
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6tumour dose of greater than or equal to 10% (13).With the advance in technology, the
more sophisticated type of 3-DCRT called IMRT is applied in order to extend the
principle of more dose to tumour while sparing the normal tissues (14).
1.2.2.3 Brachytherapy
The accuracy of this technique has improved with the use of CT and ultrasound-guided
implant techniques. This treatment can be used as monotherapy in patients with T1/T2a
disease, a Gleason score of 2 to 6 and a PSA <10 ng/ml, or as a boost to EBRT in
T2b/T2c disease. It is not recommended for patients with a Gleason score of 7 to 10 or
PSA > 10 ng/ml. The implants can be permanent or temporary, using high or low dose
rates. It offers potential biological advantages over External Beam Radiotherapy but data
on clinical relevance is still scarce (14).
1.3  Local control with different treatment approaches
1.3.1 Radical prostatectomy
At Johns Hopkins Hospital, Han et al. (15) reported the long term PSA relapse free
survival and cancer specific survival after radical prostatectomy. For 2404 patients with
a mean follow up of 6.3 years, the  PSA free survival was 84%, 74%, 64% at 5, 10, 15
years, respectively. The biochemical recurrence rate was 17% and the 15-year survival
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7was 66%. The biochemical recurrence rate was influenced by the clinical stage, Gleason
score and the pre-treatment PSA.
The improvement in surgical results is probably due to the improvement in patient
selection and the addition of postoperative radiotherapy (16).
1.3.2 EBRT
From studies before the PSA era and also during the PSA relapse free survival period, it
became clear that conventional doses of EBRT do not have the capacity to control the
disease and eradicate the cancer.
A study at MD Anderson by Zagar KZ et al. (17) demonstrated that even among patients
with PSA<10 ng/ml, there was continuous decline in the PSA relapse free survival.
The outcome of patients with T3 stage disease treated at American College of Radiology
showed 7-year local recurrence rates of 36% for 60 to 65 Gy, 32% for 65 to70 Gy and
24% for more than 70 Gy. This provided evidence that the total dose required to control
prostate cancer exceeded 70 Gy (1). However efforts to give more than 70 Gy using
conventional methods resulted in unacceptable complications.
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81.3.3 Brachytherapy
Local control of prostate cancer depends on the pre-treatment PSA, Gleason score,
clinical stage and the radiation dose given. For patients with a pre-treatment PSA of <10
ng/ml, brachytherapy alone has produced good results comparable to RP (1).
1.3.4 EBRT with dose escalation
Both retrospective and prospective studies have demonstrated improved PSA relapse free
survival with dose escalation which is possible with the use of 3-DCRT (18, 19). Single
institution trials have confirmed an advantage of high dose escalation in management of
localised prostate cancer (1).
This has been confirmed in the recent update of a phase III randomised trial from M D.
Anderson by Pollack et al. (20) They studied 301 patients with organ confined tumours
who were randomised to receive a total of 70 Gy by conventional EBRT or conventional
EBRT followed by a boost using a 3-dimensional conformal radiotherapy (3DCRT) boost
to total dose of 78 Gy. The freedom from clinical or biochemical failure was 64% and
70% respectively with a p-value of 0.03. For patients with PSA < 10 ng/ml, there was no
advantage for the higher dose.
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9Hanks et al. (21) performed a study at the Fox Chase Cancer Center with the purpose of
defining the appropriate dose for individual patients with 3DCRT. Patients were divided
into 3 groups by PSA <10 ng/ml, 10-19.9 ng/ml and ? 20 ng/ml. They were further
subdivided into 6 subgroups by the presence of either favourable or unfavourable
characteristics. The favourable characteristics were Tumour stage (T) 1 and 2a, Gleason
Score (G/S) < 6 and no perineural invasion. The unfavourable characteristics were
Tumour stage (T) 2b and 3, Gleason Score 7-10 and perineural invasion.
The five year bNED rate was estimated using the dose response function and 73 Gy was
compared with 78 Gy. Patients with PSA<10 ng/ml and favourable features, as well as
those with PSA ?20 ng/ml with unfavourable features had no dose response with dose
escalation, whereas the intermediate risk patient groups had a dose response ranging from
15 %  to 43%.
1.4 Sequelae of treatment
1.4.1 Radical prostatectomy
Side effects vary with the surgeon and whether a unilateral or bilateral nerve-sparing
surgery technique is used. The acute side effects are pain, transient incontinence, 5 to
50% blood loss of 300-4000 mls and a mortality of 1 to 2%. The incontinence recovery
depends on the age. Similarly, the incidence of impotence varies with age especially in
patients younger than 70 years (22).
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1.4.2 EBRT
Conventional radiotherapy doses are well tolerated and acute reactions usually occur in
the  3rd week of treatment and resolve within a few weeks after treatment. Late
complications are rare. The rate of complications increases as the dose exceeds 70 Gy
and the dose limiting factor is rectal toxicity. Stoley et al. (23) studied the rectal toxicity
of patients treated at the MD Anderson Hospital. The 5-year actuarial risk for late grade 2
rectal toxicity was 14% for 70 Gy and 21% for 78 Gy. Analysis of the DVHs of the
rectum for patients treated to 78 Gy showed that there was a correlation between the
percentage of rectum treated to more than 70 Gy and the likelihood of rectal toxicity.
 Dearnley DP et al. (24) compared radiation side effects with conformal versus
conventional radiation therapy for prostate cancer in a randomised trial. 223 patients were
treated up to 64 Gy at 2 Gy per fraction. The primary end point was development of late
complications measured using the Radiation Therapy and Oncology Group (RTOG)
toxicity criteria (25). Fewer men developed proctitis in the conformal group than in the
conventional group (37 vs. 56% respectively, with grade I p = 0.004 and Grade II p =
0.01). There was no difference in the bladder toxicity. This study demonstrated that there
was a reduction in rectal toxicity with 3DCRT.
Intensity modulated radiation therapy (IMRT) has further reduced the incidence of both
acute and late toxicity compared to 3DCRT (26). The 3-year actuarial incidence rates of
grade 2 rectal toxicity in patients treated with 81 Gy was 2% using IMRT compared to
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14% in 3DCRT with p=0.005. DVHs have been shown to predict rectal toxicity and it is
recommended that not more than 25% of the whole rectal volume should get more than
72 Gy (27). In these studies, rectal toxicity was graded using the RTOG toxicity criteria
(Table 4).
1.5 Immobilisation
Large day- to- day setup errors greater than 0.5 cm can be significantly reduced by use of
patient immobilisation devices and such several devices have been used (28).Although
this reduces the risk of large errors, the potential for organ movement limits the use of
very tight margins and Several studies have demonstrated that the prostate moves during
treatment (29, 30, 31, 32). Therefore, immobilisation when using 3DCRT or IMRT
includes patient immobilisation and in some instances, target organ immobilisation as
well. In order to minimize the dose to an organ at risk with dose escalation and ensure
coverage of the clinical target volume during treatment delivery when using 3DCRT and
IMRT, the movement of the target must also be minimised.
Several methods have been described to overcome the problem by using ultrasound
system or implanted prostate markers (33, 34, 35, 36). The most recent, highly technical
method described by Wong JR et al. (37) used a CT-linear accelerator combination
together in the treatment room sharing the same patient support system. Daily intrinsic
prostate movement could be corrected before each therapy session.
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Several studies have demonstrated that a rectal balloon can be used to spare the dose to
the rectum and also immobilize the prostate (38, 39). Wachter et al. (34) described a
simple method of using a rectal balloon to immobilise the prostate and also reduce rectal
variations during treatment.10 patients with localised disease were treated with 3DCRT.
CT scans, with or without a rectal balloon, were taken at 3 different intervals during
treatment. The maximum anterior/posterior displacement and rectal filling variations
during treatment were significantly reduced with p-values of 0.008 and 0.04,
respectively.
1.6 ICRU recommendations
In all above methods, the ICRU recommendation must be followed when contouring the
target organ and the normal tissues. The International Commission of Radiation Units
(ICRU) reports numbers 50 (40) and 62 (41) clearly define the volumes considered for
the treatment of patients with malignant disease. GTV and CTV represent the volumes of
known or suspected disease and organ at risk volumes (OARV`s) represent the normal
tissues at risk.
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1.7 Hypothesis
In the intermediate risk group of prostatic cancer patients treated at Johannesburg
Hospital, improved prostate immobilization and rectal dose sparing can be achieved using
a Foleys rectal balloon catheter.
1.8 Study Objectives
Primary
1. To study the influence of the rectal balloon on prostate motion in patients treated
with 3-dimensional conformal radiation therapy with dose escalation at
Johannesburg Hospital
2. The effect of the rectal balloon on the dose volume histograms of the whole
rectum during treatment with 3-dimensional conformal radiation therapy with
dose escalation at Johannesburg Hospital.
Secondary
1. Investigation of acute rectal complications when using the rectal balloon with
dose escalation.
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2.0   MATERIALS AND METHODS
2.1 Ethics
The study was approved by the Post Graduate Committee (appendix D)
And by the Ethics Committee of the University of the Witwatersrand for research on
human subjects prior to commencing data collection (appendix C).
Written consent was obtained from the patients before enrolling them in the trial and the
information leaflet and informed consent template for the University of the
Witwatersrand was used.
2.2 Study population
This was a prospective study of adult male patients referred to radiation oncology
department with histologically proven cancer of the prostate between January 2005 and
December 2006. Patients were stratified according to Fox Chase prognostic index (table
2) and 10 patients in the intermediate group with Eastern Co-operative Oncology Group
(ECOG) (42) status 0-2 (table 3) were recruited. Each patient acted as his own control in
this study.
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Inclusion Criteria
Histologically proven prostate cancer patients with ECOG performance Score of 1 to 2
and intermediate risk group according to Fox Chase prognostic index were recruited.
 Exclusion criteria
Patients with the history of previous pelvic irradiation, medical contraindications to
radiation therapy or the inability to consent for the trial, were excluded from the trial
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 Table 2. Fox Chase prognostic index for cancer of prostate.  Hanks et al (21)
Risk group Feature
 Low PSA<10 ng/ml + F F
 Intermediate PSA<10 ng/ml + UF
Or PSA 10-20 ng/ml + UF or FF
Or PSA >20 ng/ml + FF
High PSA>20 ng/ml + UF
UF refers to:  stage T2b or T3 FF refers to:        Stage T1/T2a
                                   Gleason score 7-10                              G/Score 2-6
                                    pn   +ve                                 Pn -ve
KEY:
PSA= prostate specific antigen
FF =Favorable features
UF= Unfavorable features
Pn= Perineural invasion
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  Table 3. ECOG performance score.  Skeel (42)
Score ECOG performance status
0 Normal activity, asymptomatic
1 Symptomatic, but fully ambulant
2 Symptomatic, in bed less than 50% of
daytime
3 Symptomatic, in bed more than 50% of
daytime
4 Bedridden, almost 100% of day time in bed
 Table 4. RTOG acute toxicity score of the rectum.  Cox JD et al (25)
Score Toxicity
0 Normal
1 Proctitis
2 Diarrhoea
3 Painless rectal bleeding
4 Ulceration
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3.0. METHODS
3.1 Patient preparation for radiotherapy
To achieve reproducible positioning during treatment and CT scanning, every patient had
a personalized cast. The patient was immobilized in a polyurethane cast moulded from
the waist to the feet. The patients were positioned supine with their knees slightly flexed
and feet together.
3.2. Simulation
A reference simulation was performed for all further positioning and the patient was
permanently tattooed to record the reference position. CT scans in the treatment position
were then performed.
3.3. CT-scan imaging
Each patient had 6 CT scans during their treatment management. All CT scans (somatom
DR3TM) were done in the immobilized treatment position. Sequential scanning was used
for all cases.
No rectal preparation was done for the first scan. After 10 Gy of the EBRT, two scan
series were performed following overnight rectal preparation with a rectal suppository to
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empty the rectum. One scan was performed with the balloon in the rectum and the other
with no rectal balloon. The scan with the rectal balloon was used to plan the 3-field boost
treatment.
Similarly, the 2 scans series were repeated at the start of the booster treatment usually at
20 Gy of the large field treatment. The 6th scan was done on the day of the 2nd booster
treatment, usually at 40 Gy of the large field treatment, with no rectal balloon.
Scanning of all the 6 image sets was done from the level of the anterior superior iliac
spine (ASIS) to the lower border of the sacro-iliac joint in 1 cm slices, then inferiorly to 1
cm below the lower border of ischial-tuberosity using 0.5 cm slices. All scans were
electronically transferred to Helax TMSTM planning system for 3-dimensional treatment
planning. Software Version 5. 1.1 was used for all cases.
The characteristics of each CT scan performed are shown in table 5 below.
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Table 5. Showing CT-scan characteristics for each patient
CT-scan
number
Time of scan Rectal
preparation
30 cc rectal
balloon used
1 Initiation of treatment
planning
no no
2
3
10Gy of EBRT
treatment
Yes
Yes
Yes
No
4
5
1st booster treatment Yes
Yes
Yes
No
6 2nd booster treatment Yes No
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3.4. Rectal balloon
A two-way Foleys catheter gauge 15 was used as the rectal balloon to immobilize the
prostate. The patient was instructed to lie on the lateral side; the Foleys catheter was
lubricated with K-Y jelly and gently introduced into the patient’s rectum. 30 cc of
contrast was introduced into the balloon of the catheter using a 50 cc plastic syringe. The
catheter was pulled down till resistance was felt and then strapped to the patient’s thigh
using plaster. The patient was again positioned in the treatment position. The balloon was
confirmed to be in the correct position on the CT topogram. At least 2/3 of the diameter
of the balloon was required to be behind the symphysis pubis.
 The position of the anal verge was marked on the catheter for future positioning of the
same catheter in the rectum during treatment. After the procedure, the balloon was
deflated and removed, cleaned with water and stored for all subsequent procedures for the
same patient.
3.5. Organ contouring
The contours for the prostate and the organ at risk volumes were outlined by the
investigator. These organs included the prostate, seminal vesicles, bladder, rectum and
the femoral heads. All volumes in all cases were checked and approved by a supervisor
(an experienced radiation oncologist) before treatment planning.
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For the first and last CT Scans, the GTV included the prostate and seminal vesicles. Only
the prostate was outlined for the other scans. The OAR volumes were the same for all the
CT scans. The external contour of the rectum was delineated from the lower border of the
sacro-iliac joint to the anal–rectal junction. This was considered the total rectal volume in
all cases and Dose volume histograms were generated for all the volumes.
3.6. Planning and treatment
Plans were generated for all the patient scans. A 6-field conformal technique was used for
the initial treatment planning of each patient. A 3-dimensional internal margin of 1.5 cm
was automatically added to the GTV, except posteriorly where a 0.8 cm margin was used.
Six conformal fields with apertures shaped to fit the Beams Eyes View of each port as
defined by the internal margin, were used in the initial planning. A total of 66 Gy was
prescribed to the mean dose of the internal volume, based on the DVH.
The initial treatment plan was delivered according to the distribution obtained from the
first CT scan. This was copied in its entirety onto the last CT scan using the same
reference point. These two plans were then compared to note the effect of rectal
preparation on the rectal volume.
For all the other CT scans, 3-field plans for the boost treatment were generated using 2
lateral opposing fields and 1 anterior field. In these plans, the GTV was the prostate only
and no internal margin was added. In order to obtain a non-divergent beam posteriorly, an
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independent jaw was used. A total of 12 Gy was prescribed for these plans to the 100%
isodose line at 4 Gy per fraction. No beam shaping devices were used in these plans.
DVHs for the organs at risk were also generated for these plans. A dose constraint of 72
Gy to not more than 25% volume of the rectum was used for the rectal OAR volume. The
CT scan obtained with the rectal balloon was used for the treatment of the boost.
Patients were treated daily from Monday to Friday at 2 Gy per fraction, one fraction per
day to 66 Gy with a 6-field conformal plan. A concomitant boost of 4 Gy given weekly to
12 Gy was given after 20 Gy. The boost was given with the rectal balloon inserted using
the same procedure as described for the CT scanning. All boosters were given after rectal
preparation the previous day. Portal films to establish the isocentre placement were done
at each boost fraction and were approved by the same radiation oncologist before
treatment was delivered. Patients were reviewed weekly and as requested.
3.7. Data collection
The data was collected between January 2005 and December 2006 and for consistency,
the CT scans were stored and analyzed at the end of the study. For the DVHs, data sheets
were used to record the percentage of the prescribed dose received by percentage rectal
volume. The results from the plans with the rectal balloon were compared to those with
no rectal balloon. For the first and last CT scans, the effect of the preparation schedule on
the volume of rectum was compared. For prostate movement, the first scan series was
used as the standard to which the second series was compared to measure changes in the
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prostate position. The beams eye views of the boost plan were transferred to the rest of
the image series using the anatomical landmarks in both the AP and lateral views. The
position of the posterior and inferior border of the prostate in relation to the ICRU
reference point was recorded in millimeters and compared to the similar borders on the
reference scans to get the displacement in millimeters. Rectal toxicity scores were
recorded on a weekly basis during treatment.
3.8. Data analysis
Statistical Package for Social Sciences and the Mann Whitney U test was used to
compare the DVHs of the whole rectum with and without a rectal balloon. The
proportions of patients with rectal movement above and below 5 mm were compared
using the chi-square test.
.
Descriptive statistics were used to describe the incidence of acute rectal complications
(Table 4).
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4.0. RESULTS
Two patients had incomplete data at the end of trial due to technical problems. Eight
patients were available for analyses. The mean age of the patients was 65 years, ranging
from 52 years to 73 years of age. All had ECOG performance scores of 1 or 2 at the
beginning of the study.
Table 6. The Effect of Rectal Preparation on the Prostate Volume, Rectal Volume,
and the Prescribed Dose to the Prostate
Keys to scans Mean
ranks
P
value
Percentage of prescribed dose received
by 90% of the prostate.
No preparation
With preparation
8.69
8.31
NS
Prostate volume No preparation
With preparation
10.19
6.81
NS
Mean dose to prostate No preparation
With preparation
9.38
7.63
NS
Total volume of the rectum No preparation
With preparation
11.19
5.81
0.024
KEY
No Preparation:       no preparation of the rectum (scan 1)
With Preparation:      With preparation of the rectum (scan 6)
NS:                Non significant
p value based on Mann Whitney test
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Table 7.  The effect of the rectal balloon on the total volume of the rectum, mean
dose to the  prostate, prostate volume and percentage dose received by 90% of the
prostate volume
Keys to scans  Total Number
of scans
Mean
ranks
p
value
% dose received by 90% of
the prostate.
Rectal Balloon
No Balloon
16
16
20.09
12.91
0.030
Prostate volume Rectal Balloon
No Balloon
16
16
15.56
17.44
NS
Mean dose to prostate Rectal Balloon
No Balloon
16
16
19.06
13.06
0.038
Total volume of the rectum Rectal Balloon
No Balloon
16
16
22.38
10.63
<0.005
KEY
Rectal Balloon:     With use of rectal balloon (scan 2 and 4)
No Balloon:      No rectal balloon used (scan 3 and 5)
p value based on Mann Whitney test
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4.1 Prostate volume
The prostate volumes varied in the eight patients with a median of 34 cc and maximum of
79 cc Table 8.
Table 8.   Prostate volume in the 8 patients as derived from the 32 CT scans
Number of CT
scans
Maximum prostate
volume
 Minimum prostate
volume
Median Mean
32 79 cc 18 cc 34 cc 40.31
For prostate volumes, the CT-scan 1and 6 were not considered because during planning,
the 1.5 cm margin was automatically added to the prostate by the treatment  planning
computer and this was the volume which was used on the 2 scans.
4.2 Rectum Volume
The rectal volumes were measured using the external contour in all the CT scans. Rectal
preparation (table 6), significantly reduced the volume of the rectum, p=0.024 (2-tailed)
using Mann Whitney test. The insertion of the rectal balloon (Table 7) also lead to a
significant increase in the total rectal volume p <0.05 (Mann Whitney test) but this
increase was probably due to the 30 cc of contrast in balloon. Figure 1and 2 shows axial
scans through the iso-centre with and without a rectal balloon in patient 8.
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Fig. 1  With a rectal balloon
Fig. 2  Without  rectal balloon
Figure 1 and 2. Axial reference CT scans at the centre of prostate for patient number 8
with and without a rectal balloon in relation to the prostate
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4.2.1 Effect of rectal balloon on DVHs of the rectum
In this study, the doses received by 1% and 2% of the volume of the rectum were slightly
reduced by the use of the rectal balloon (p=>0.05). The dose received by 50% of the
volume of the rectum was increased with the use of a rectal balloon (p=>0.05). There was
no statistically significant difference in the DVH of the whole rectum with the use of a 30
cc rectal balloon as shown in Table 9. Figures 3 and 4 show the DVHs for a patient with a
rectal balloon and without the rectal balloon.
Table 9. The effect of the rectal balloon on mean percentage dose received by the
percentage volume of the whole rectum for the 8 patients
%rectal volume    1 2   20  25 30 40 50 60 70
% dose with balloon 55 52.88 37.13 33 31.38 33.88 46.36 27.94 20.38
%  dose with no balloon 57.125 54.38 33.81 32.82 31.32 32.82 29.88 24.63 17.88
p value (2-tailed) 0.720 0.36 0.39 0.99 0.73 0.72 0.09 0.10 0.21
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Fig. 3   DVH with a balloon
Fig. 4  DVH without a balloon
Fig 3 and 4. The DVHs of the rectum for a patient with and without a rectal balloon in
position.
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4.3.0. Prostate movement
The prostate displacements were recorded as the difference between the prostate position
on the lateral beam's eye view between the reference scan and the equivalent scan in the
second series. The distances were measured from the ICRU reference point to the inferior
and posterior border of the prostate for the superior/inferior and anterior/posterior
displacements, respectively. Displacements are shown in table 10 below.
Table10. The displacement of the prostate result with and without the rectal balloon
in 8 patients
Group Patients with displacements
? 5 mm
Patients with displacements
> 5 mm
p value
(Chi-square tests)
A  7 1
B  3 5
C  6 2
D  4 4
0.049
KEY
A:                                                           Superior/inferior displacement with balloon
B:                                                          Superior/inferior displacement without balloon
C:                                                          Anterior/posterior displacement with balloon
D:                                                         Anterior/posterior displacement without balloon
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4.3.1. Effect of Rectal Balloon on prostate displacement
Superior inferior
The mean superior inferior displacement with and without the balloon was 2.38 mm and
5.75 mm respectively. Only one patient had a displacement of more than 5 mm with a
rectal balloon compared to 5 patients with no rectal balloon. (Table 10).
Anterior posterior
The mean anterior posterior displacement was 4 mm with the rectal balloon and 5 mm
without the rectal balloon. Two patients had a displacement above 5 mm with the rectal
balloon compared to 4 patients with no rectal balloon.
With the rectal balloon, there was a significant reduction in the proportion of patients
with displacements above and below 5 mm in both the anterior-posterior and inferior-
superior distances (p=0.049) using chi-square test. The percentage of the prescribed dose
received by the prostate and the mean dose were significantly different with a balloon
p=0.03 and 0.038, respectively based on the Mann Whitney test.
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4.4 Rectal toxicity
No treatment interruptions due to failure to tolerate rectal balloon or due to acute rectal
toxicity were noted and all patients completed the 6-week treatment course.
Table 11 shows the rectal toxicity recorded at the end of the sixth week of treatment.
Table 11. The acute rectal toxicity score of the 8 patients
GRADE 0 1 2 3
NUMBER OF PATIENTS 1         6 1 0
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5 DISCUSSION
5.1 3-Dimensional conformal radiotherapy and IMRT treatment techniques call for extra-
ordinary accuracy in directing external beam radiation (43). Previous studies have
confirmed prostate motion during treatment (29, 30, 31, 32). Methods have been
described and are used to overcome this problem especially during dose escalation (33,
34, 35, 36). The objectives in all these techniques are to minimize toxicity to OAR and to
ensure tumour coverage all the time.
In this study, we proposed the use of a Foleys urethral catheter as a rectal balloon as an
alternative to all other methods described. The advantage seen in our patient population
have been several-fold. By using the rectal balloon, which is easily available in the
hospital, we can achieve dose escalation while reducing the rectal toxicity and achieving
immobilization of the prostate at the same time.
This paper discusses the results of a prospective study at Johannesburg Hospital using
Foleys catheter filled with 30 cc of contrast as a rectal balloon to achieve similar goals.
5.2 Effect of Rectal balloon on DVH
Van Lin EN, et al (44) investigated the dosimetric consequences and endorectal wall
effect of three different endorectal balloon for three Dimensional Conformal
Radiotherapy and Intensity-modulated radiotherapy for prostate cancer. They looked at
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284 treatment plans from 20 patients and calculated the rectal wall mean dose, rectal wall
mean tissue complication probability and the absolute rectal wall volume exposed to 50
Gy or higher and 70 Gy or higher. Partial dose distribution analysis, inner rectal wall
maps and dose surface histograms were generated. In case of 3-DCRT there was a
statistically significant reduction in all the parameters, however with IMRT, a statistically
significant reduction on the rectal wall dose parameters could not be demonstrated for
any of the endorectal balloon, however, both lead to a reduced late toxicity due to
reduction of the relative inner wall surface exposed to high doses.
Wachter S (34) investigated the variations in the rectal volumes and its DVH during
treatment with conformal radiotherapy. They studied the influence of a rectal balloon on
the DVH of the anterior and posterior rectal wall volumes, the entire rectal wall and
whole rectal volume in 10 patients. They used a commercial rectal balloon inflated with
40 ml of air. No statistically significant difference was reported with the use of their
rectal balloon on the DVH of the whole rectum.
In our study there was a slight reduction in the dose received by 1 - 2% of the rectal
volume which may represent the rectal wall dose but this was not statistically significant.
There was also a non-significant increase in the percentage dose received by 50% of the
volume of the rectum due to the balloon pushing the anterior rectal wall towards the
symphysis pubis. In the Van Lin study they looked at the rectal wall dose and there was a
significant reduction with the use of a balloon. A slight reduction in the dose received by
1-2% in our study may be the representative of the rectal wall dose as reported in the Van
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Lin study. The current study did not look at the rectal wall dose but the dose to the whole
rectal volume. Similar findings to those reported by Wachter were found in our study
regarding the effect of the rectal balloon on the DVHs of the whole rectum.  Both studies
did not find any statistically significant difference with the use of a rectal balloon on the
DVH of the whole rectum.
5.3.0 Effect of rectal preparation on the rectal volume
Rectal preparation significantly reduced the volume of the rectum (p=0.024). This
implies that the rectum is not always empty and that rectal position and filling can vary
over the short period of time due to peristalsis and bowel gas movement. Padhni et al (45)
concluded that rectal movements are related to rectal distention and results in significant
prostate displacements during daily fractionations. Stasi M, et al (46) Studied rectal
emptying before treatment to assess if it limits the variation of the rectum volume
parameters during 3-DCRT of the prostate. Ten patients had planning CT-scans to a total
of 126 scans. They were asked to empty the rectum before every CT scan and before
treatment delivery. Volume analysis  showed a slight systematic variation of the rectal
volume between planning and treatment and the average rectal volume during therapy
was larger than at the planning CT in 8/10 patients. In this study, the practice of carefully
emptying the rectum during simulation and therapy for prostate cancer reduced the
impact of organ motion on dose-volume parameters of the rectum. This variation in rectal
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distention was reduced in our study by using rectal preparation and is similar to that
reported by the above studies.
5.3.1. Effect of rectal balloon on prostate movement
A number of studies (29, 31, 47) have shown that there is displacement of prostate with
rectal filling variation and this is shown the table 12.
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Table 12 Standard deviations of prostate motion from various studies
Author                                                                 direction of motion
                                                  L-R (mm)            A-P (mm)           superior-inferior
Edward Melian et al (29)                1.2                         4.0                        3.1
John A. Antolak et al (31)             0.9                        4.1                         3.6
Volker Rudat et al (47 )                                              2.8                         1.4
KEY
L-R :      Left- Right
 A/P:      Anterior-Posterior
Langen et al. (29) noted that despite different processes and study end points used, there
is agreement that displacement is greatest in the anterior-posterior direction compared to
the superior-inferior direction with standard deviations ranging from 1.5 mm to 4.1 mm
and 1.7 mm to 4.5 mm, respectively.
Dawson et al. (48) studied 6 patients with weekly CT scans, in the supine position with
empty bladders. Relative to the initial CT scan, displacement of prostate was noted to be
7.3 mm and 9.3 mm anterior posterior and superior inferior, respectively, demonstrating
prostate movement.
Crooks, et al (49) studied the prostate motion, minimum motion was noted in the lateral
direction with 0.1 to 0.5 cm, and in cranial caudal axis was usually 0.5 cm on average and
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43% showed more than 0.5 cm displacement and 11% more than 1 cm displacement. In
the posterior direction 60% shown more than 0.5 cm and 30% shown more than 1 cm
displacement.
McGrany et al. (39) studied prostate immobilization using a rectal balloon in 10 patients
using CT-fusion on patients who had previously received Gold implants as internal
markers. They noted a minimal displacement in the Anterior-Posterior (A/P) and lateral
directions with a rectal balloon of approximately 1 mm. The superior-inferior standard
deviation was 1.7 with a mean of 0.92 mm.
D’Amico et al. (33) studied immobilization of prostate using 60 cc of air in a rectal
balloon designed specially to conform to the shape of prostate-rectal interface in 10
patients who underwent prostate brachytherapy using permanent radioactive seeds.
Coordinates of the  implant sources were compared at one minute intervals, and the
mean displacement of the  prostate gland when the intrarectal balloon was present was
1.3 mm versus 1.8 mm when it was not used (p=0.03).
 Wachter et al. (34) studied the influence of a rectal balloon inflated with 40 cc of air as
internal immobilization of the prostate. Six CT scans at 3 intervals were used and
displacements were measured on the beams eye view with and without a rectal balloon.
With the rectal balloon, the Anterior-Posterior (A/P) displacement was reduced p=0.008
and displacements >5 mm were noted in 2/10 patients. Superior inferior (S/I)
displacements were not measured in this study.
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In the current study, more displacement was recorded in the superior inferior direction
compared to the anterior posterior direction with a mean of 5.7 mm and 5.00 mm
respectively with no rectal balloon. When a rectal balloon was used, there was a
reduction in the displacement in the superior inferior direction of a mean of 2.38 mm.  In
the anterior posterior direction with the balloon, the mean was 4.00 mm. This may have
been due to the fact that the rectal balloon used could not conform to the prostate.
When displacements of more than 5 mm were compared with and without the balloon,
only 1/8 patients had a displacement above 5 mm with the balloon compared to 5/8
without the balloon in the superior-inferior (S/I) direction. Likewise, 2/8 compared to 4/8
in the A/P direction respectively. There was a significant increase in the dose received by
90% of prostate with the balloon (p=0.03) and also in the mean dose to the prostate
volume (p=0.038). The poor coverage of the prostate with no balloon is attributed to the
displacement.
When the above studies without endorectal balloon are compared with the studies with
the endorectal balloon including results from our study, prostate displacements more than
5mm are greatly reduced, this makes it possible to use tight margins on the prostate
during 3-DCRT or IMRT with dose escalation treatment resulting in reduced rectal
toxicity.
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5.3.2. Acute toxicity during treatment
Ronson et al. (50) did a retrospective study to evaluate the rectal tolerance of conformal
prostate treatment with a rectal balloon in 3561 patients. 97% tolerated a rectal balloon
throughout the treatment course, and 2.7% declined balloon insertion for one or two
treatments but tolerated it for up to 85% of their treatment.
Kannan, et al. (51) looked at survival and rectal toxicity for patients with adenocarcinoma
of prostate treated with three Dimensional Conformal radiotherapy Out of the 51 patients
in the study, the acute rectal toxicity using the RTOG criteria was grade 0 in 4 patients,
grade 1 in 31 patients and grade 2 in 16 patients. No grade 3 or 4 toxicities were recorded
Bastasch MD, et al (52) reported patient tolerance and acute anorectal toxicity of an
endorectal balloon used for prostate cancer immobilization during 35 daily fractions.
Patients were treated with IMRT and an endorectal balloon catheter was inserted daily
and inflated with 100ml of air for immobilizing the prostate gland.  They received a mean
dose of 77 Gy. None of the 396 patients stopped treatment because of associated toxicity.
13.9% and 18.4% had RTOG grade 1and 2 toxicity respectively and no RTOG grade 3
and 4 toxicities were recorded.
In this study, all 8 patients tolerated the balloon throughout the treatment. There were no
complaints about discomfort and no treatment was discontinued because of the use of the
rectal balloon. No grade 3 acute toxicity was reported in the study. Patients reporting
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grade 2 toxicity had ECOG 2 performance status at the beginning of the treatment,
however all completed treatment with no deterioration in performance status. The above
results compare well with the results from previous studies indicating that the rectal
balloon is well tolerated.
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6.0. CONCLUSION
A simple method of using a Foleys rectal balloon catheter to achieve the immobilization
of the prostate during treatment with 3-dimensional conformal radiotherapy with dose
escalation has been presented.
There was no effect on the DVH of the whole rectum with the use of a 30 cc rectal
balloon; however there was a non-significant reduction in the volume receiving a higher
percentage dose with the use of a rectal balloon.
No Grade 3 acute rectal toxicity was recorded in the 8 patients. No comment can be made
regarding chronic toxicity as the follow up period is too short.
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Appendix   A
THE UPDATED PARTIN TABLES
Gleason ScorePSA Range
(ng/mL) Pathologic Stage 2-4 5-6 3+4=7 4+3=7 8-10
Organ confined 95 (89-99) 90 (88-93) 79 (74-85) 71 (62-79) 66 (54-76)
Extraprostatic
extension 5 (1-11) 9 (7-12) 17 (13-23) 25 (18-34) 28 (20-38)
Seminal vesicle (+) - 0 (0-1) 2 (1-5) 2 (1-5) 4 (1-10)
0-2.5
Lymph node (+) - - 1 (0-2) 1 (0-4) 1 (0-4)
Organ confined 92 (82-98) 84 (81-86) 68 (62-74) 58 (48-67) 52 (41-63)
Extraprostatic
extension 8 (2-18) 15 (13-18) 27 (22-33) 37 (29-46) 40 (31-50)
Seminal vesicle (+) - 1 (0-1) 4 (2-7) 4 (1-7) 6 (3-12)
2.6-4.0
Lymph node (+) - - 1 (0-2) 1 (0-3) 1 (0-4)
Organ confined 90 (78-98) 80 (78-83) 63 (58-68) 52 (43-60) 46 (36-56)
Extraprostatic
extension 10 (2-22) 19 (16-21) 32 (27-36) 42 (35-50) 45 (36-54)
Seminal vesicle (+) - 1 (0-1) 3 (2-5) 3 (1-6) 5 (3-9)
4.1-6.0
Lymph node (+) - 0 (0-1) 2 (1-3) 3 (1-5) 3 (1-6)
Organ confined 87 (73-97) 75 (72-77) 54 (49-59) 43 (35-51) 37 (28-46)
Extraprostatic
extension 13 (3-27) 23 (21-25) 36 (32-40) 47 (40-54) 48 (39-57)
Seminal vesicle (+) - 2 (2-3) 8 (6-11) 8 (4-12) 13 (8-19)
6.1-10.0
Lymph node (+) - 0 (0-1) 2 (1-3) 2 (1-4) 3 (1-5)
Organ confined 80 (61-95) 62 (58-64) 37 (32-42) 27 (21-34) 22 (16-30)
Extraprostatic
extension 20 (5-39) 33 (30-36) 43 (38-48) 51 (44-59) 50 (42-59)
Seminal vesicle (+) - 4 (3-5) 12 (9-17) 11 (6-17) 17 (10-25)
>10.0
Lymph node (+) - 2 (1-3) 8 (5-11) 10 (5-17) 11 (5-18)
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 TABLE II. Clinical Stage T2a (palpable < 1 .2 of one lobe))
Gleason ScorePSA Range
(ng/mL) Pathologic Stage 2-4 5-6 3+4=7 4+3=7 8-10
Organ confined 91 (79-98) 81 (77-85) 64 (56-71) 53 (43-63) 47 (35-59)
Extraprostatic
extension 9 (2-21) 17 (13-21) 29 (23-36) 40 (30-49 42 (32-53)
Seminal vesicle (+) - 1 (0-2) 5 (1-9) 4 (1-9) 7 (2-16)
0-2.5
Lymph node (+) - 0 (0-1) 2 (0-5) 3 (0-8) 3 (0-9)
Organ confined 85 (69-96)) 71 (66-75) 50 (43-57) 39 (30-48) 33 (24-44
Extraprostatic
extension 15 (4-31) 27 (23-31) 41 (35-48) 52 (43-61) 53 (44-63)
Seminal vesicle (+) - 2 (1-3) 7 (3-12) 6 (2-12) 10 (4-18)
2.6-4.0
Lymph node (+) - 0 (0-1) 2 (0-4) 2 (0-6) 3 (0-8)
Organ confined 81 (63-95) 66 (62-70) 44 (39-50) 33 (25-41) 28 (20-37)
Extraprostatic
extension 19 (5-37) 32 (28-36) 46 (40-52) 56 (48-64) 58 (49-66)
Seminal vesicle (+) - 1 (1-2) 5 (3-8) 5 (2-8) 8 (4-13)
4.1-6.0
Lymph node (+) - 1 (0-2) 4 (2-7) 6 (3-11) 6 (2-12)
Organ confined 76 (56-94) 58 (54-61) 35 (30-40) 25 (19-32) 21 (15-28)
Extraprostatic
extension 24 (6-44) 37 (34-41) 49 (43-54) 58 (51-66) 57 (48-65)
Seminal vesicle (+) - 4 (3-5) 13 (9-18) 11 (6-17) 17 (11-26)
6.1-10.0
Lymph node (+) - 1 (0-2) 3 (2-6) 5 (2-8) 5 (2-10)
Organ confined 65 (43-89) 42 (38-46) 20 (17-24) 14 (10-18) 11 (7-15)
Extraprostatic
extension 35 (11-57) 47 (43-52) 49 (43-55) 55 (46-64) 52 (41-62)
Seminal vesicle (+) - 6 (4-8) 16 (11-22) 13 (7-20) 19 (12-29)
>10.0
Lymph node (+) - 4 (3-7) 14 (9-21) 18 (10-27) 17 (9-29)
KEY: PSA = prostate-specific antigen.
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TABLE III. Clinical Stage T2b (palpable > 1 .2 of one lobe, not on both lobes)
Gleason ScorePSA Range
(ng/mL) Pathologic Stage 2-4 5-6 3+4=7 4+3=7 8-10
Organ confined 88 (73-97)
75 (69-
81)
54 (46-
63)
43 (33-
54) 37 (26-49)
Extraprostatic
extension 12 (3-27)
22 (17-
28)
35 (28-
43)
45 (35-
56) 46 (35-58)
Seminal vesicle (+) - 2 (0-3) 6 (2-12) 5 (1-11) 9 (2-20)
0-2.5
Lymph node (+) - 1 (0-2) 4 (0-10) 6 (0-14) 6 (0-16)
Organ confined 80 (61-95)
63 (57-
69)
41 (33-
48)
30 (22-
39) 25 (17-34)
Extraprostatic
extension 20 (5-39)
34 (28-
40)
47 (40-
55)
57 (47-
67) 57 (46-68)
Seminal vesicle (+) - 2 (1-4) 9 (4-15) 7 (3-14) 12 (5-22)
2.6-4.0
Lymph node (+) - 1 (0-2) 3 (0-8) 4 (0-12) 5 (0-14)
Organ confined 75 (55-93)
57 (52-
63)
35 (29-
40)
25 (18-
32) 21 (14-29)
Extraprostatic
extension 25 (7-45)
39 (33-
44)
51 (44-
57)
60 (50-
68) 59 (49-69)
Seminal vesicle (+) - 2 (1-3) 7 (4-11) 5 (3-9) 9 (4-16)
4.1-6.0
Lymph node (+) - 2 (1-3) 7 (4-13) 10 (5-18) 10 (4-20)
Organ confined 69 (47-91)
49 (43-
54)
26 (22-
31)
19 (14-
25) 15 (10-21)
Extraprostatic
extension 31 (9-53)
44 (39-
49)
52 (46-
58)
60 (52-
68) 57 (48-67)
Seminal vesicle (+) - 5 (3-8) 16 (10-22) 13 (7-20) 19 (11-29)
6.1-10.0
Lymph node (+) - 2 (1-3) 6 (4-10) 8 (5-14) 8 (4-16)
Organ confined 57 (35-86)
33 (28-
38)
14 (11-
17) 9 (6-13) 7 (4-10)
Extraprostatic
extension
43 (14-
65)
52 (46-
56)
47 (40-
53)
50 (40-
60) 46 (36-59)
Seminal vesicle (+) - 8 (5-11) 17 (12-24) 13 (8-21) 19 (12-29)
>10.0
Lymph node (+) - 8 (5-12) 22 (15-30)
27 (16-
39) 27 (14-40)
KEY: PSA = prostate-specific antigen.
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TABLE IV. Clinical Stage T2c (palpable on both lobes)
Gleason ScorePSA Range
(ng/mL) Pathologic Stage 2-4 5-6 3+4=7 4+3=7 8-10
Organ confined 86 (71-97)
73 (63-
81)
51 (38-
63)
39 (26-
54) 34 (21-48)
Extraprostatic
extension 14 (3-29)
24 (17-
33)
36 (26-
48)
45 (32-
59) 47 (33-61)
Seminal vesicle (+) - 1 (0-4) 5 (1-13) 5 (1-12) 8 (2-19)
0-2.5
Lymph node (+) - 1 (0-4) 6 (0-18) 9 (0-26) 10 (0-27)
Organ confined 78 (58-94)
61 (50-
70)
38 (27-
50)
27 (18-
40) 23 (14-34)
Extraprostatic
extension 22 (6-42)
36 (27-
45)
48 (37-
59)
57 (44-
70) 57 (44-70)
Seminal vesicle (+) - 2 (1-5) 8 (2-17) 6 (2-16) 10 (3-22)
2.6-4.0
Lymph node (+) - 1 (0-4) 5 (0-15) 7 (0-21) 8 (0-22)
Organ confined 73 (52-93)
55 (44-
64)
31 (23-
41)
21 (14-
31) 18 (11-28)
Extraprostatic
extension 27 (7-48)
40 (32-
50)
50 (40-
60)
57 (43-
68) 57 (43-70)
Seminal vesicle (+) - 2 (1-4) 6 (2-11) 4 (1-10) 7 (2-15)
4.1-6.0
Lymph node (+) - 3 (1-7) 12 (5-23) 16 (6-32) 16 (6-33)
Organ confined 67 (45-91)
46 (36-
56)
24 (17-
32)
16 (10-
24) 13 (8-20)
Extraprostatic
extension 33 (9-55)
46 (37-
55)
52 (42-
61)
58 (46-
69) 56 (43-69)
Seminal vesicle (+) - 5 (2-9) 13 (6-23) 11 (4-21) 16 (6-29)
6.1-10.0
Lymph node (+) - 3 (1-6) 10 (5-18) 13 (6-25) 13 (5-26)
Organ confined 54 (32-85)
30 (21-
38) 11 (7-17) 7 (4-12) 6 (3-10)
Extraprostatic
extension
46 (15-
68)
51 (42-
60)
42 (30-
55)
43 (29-
59) 41 (27-57)
Seminal vesicle (+) - 6 (2-12) 13 (6-24) 10 (3-20) 15 (5-28)
>10.0
Lymph node (+) - 13 (6-22) 33 (18-49)
38 (20-
58) 38 (20-59)
KEY: PSA = prostate-specific antigen.
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APPENDIX B
The TNM staging of the prostate cancer
TNM definitions
Primary tumor (T)
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Clinically unapparent tumor not palpable nor visible by imaging
T1a: Tumor incidental histologic finding in ?5% of tissue resected
T1b: Tumor incidental histologic finding in >5% of tissue resected
T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA)
T2: Tumor confined within prostate*
T2a: Tumor involves 50% of one lobe or less
T2b: Tumor involves >50% of one lobe but not both lobes
T2c: Tumor involves both lobes
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T3: Tumor extends through the prostate capsule**
T3a: Extracapsular extension (unilateral or bilateral)
T3b: Tumor invades seminal vesicle(s)
T4: Tumor is fixed or invades adjacent structures other than seminal vesicles: bladder
neck, external sphincter, rectum, levator muscles, and/or pelvic wall
* [Note: Tumor that is found in one or both lobes by needle biopsy but is not palpable or
reliably visible by imaging, is classified as T1c.]
** [Note: Invasion into the prostatic apex or into (but not beyond) the prostatic capsule
is not classified as T3, but as T2.]
Regional lymph nodes (N)
Regional lymph nodes are the nodes of the true pelvis, which essentially are the pelvic
nodes below the bifurcation of the common iliac arteries. They include the following
groups (laterality does not affect the N classification): pelvic (not otherwise specified
[NOS]), hypogastric, obturator, iliac (i.e., internal, external, NOS), and sacral (lateral,
presacral, or promontory [e.g., Gerota’s], or NOS). Distant lymph nodes are outside the
confines of the true pelvis. They can be imaged using ultrasound, CT, MRI, or
lymphangiography, and include: aortic (para-aortic, periaortic, or lumbar), common iliac,
inguinal (deep), superficial inguinal (femoral), supraclavicular, cervical, scalene, and
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retroperitoneal (NOS) nodes. Although enlarged lymph nodes can occasionally be
visualized, because of a stage migration associated with PSA screening, very few
patients will be found to have nodal disease, so false-positive and false-negative results
are common when imaging tests are employed. In lieu of imaging, risk tables are
generally used to determine individual patient risk of nodal involvement. Involvement of
distant lymph nodes is classified as M1a.
NX: Regional lymph nodes were not assessed
N0: No regional lymph node metastasis
N1: Metastasis in regional lymph node(s)
Distant metastasis (M)*
MX: Distant metastasis cannot be assessed (not evaluated by any modality)
M0: No distant metastasis
M1: Distant metastasis
M1a: Nonregional lymph node(s)
M1b: Bone(s)
M1c: Other site(s) with or without bone disease
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APPENDIX F
DATA COLLECTION SHEET FOR PATIENT NO--------
DXT no-------              Hospital no---------           Age--------       Study no---------
CT scan
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of prost.
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by50%prost
vol
Prostate
Vol.
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To prostate
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2nd .scan with no
balloon
Superior  (+)
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Acute Toxicity Score of the Rectum
Week of treatment One Two Three Four Five  Six
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